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Local production of estrogen rapidly follows brain tissue injury, but the role this hormone
plays in regulating the response to neural damage or in the modulation of mediators
regulating inflammation is in many ways unclear. Using the murine BV2 microglia model
as well as primary microglia from wild-type and annexin A1 (AnxA1) null mice, we have
identified two related mechanisms whereby estradiol can modulate microglial behavior
in a receptor specific fashion. Firstly, estradiol, via estrogen receptor β (ERβ), enhanced
the phagocytic clearance of apoptotic cells, acting through increased production and
release of the protein AnxA1. Secondly, stimulation of either ERβ or the G protein coupled
estrogen receptor GPER promoted the adoption of an anti-inflammatory/pro-resolving
phenotype, an action similarly mediated through AnxA1. Together, these data suggest
the hypothesis that locally produced estrogen acts through AnxA1 to exert powerful
pro-resolving actions, controlling and limiting brain inflammation and ultimately protecting
this highly vulnerable organ. Given the high degree of receptor selectivity in evoking
these responses, we suggest that the use of selective estrogen receptor ligands may
hold therapeutic promise in the treatment of neuroinflammation, avoiding unwanted
generalized effects.
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INTRODUCTION
The neuroprotective potential of the steroid hormone estrogen has been the focus of numerous
investigations, with epidemiological and animal model studies suggesting it may protect in
conditions as diverse as stroke, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury
(1). Despite this, detailed understanding of the mechanisms underlying its actions in the brain
remains elusive.Many studies have focused upon the direct effects of estrogen upon damaged/dying
neurones, but it is only relatively recently that the relationship between estrogen and the
innate defense mechanisms of the brain, principally astrocytes and microglia, has begun to be
addressed (2, 3).
Local production of estrogen by astrocytes is one of the first responses of both male and
female brain tissue to injury (4), with this production affording significant protection in vivo
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(5). Dysregulated inflammation can be extremely deleterious for
the brain (6), hence studies have focused on suppressive actions
of estradiol, revealing its ability to limit microglial iNOS activity
(7), and production of reactive oxygen species (8), prostaglandins
(9), and inflammatory cytokines (10).
However, it is becoming increasingly clear that in the
absence of aggravating factors inflammation is naturally self-
limiting, with many classical mediators activating resolving
pathways (11). This may have significant consequences for
future therapeutic development, as generalized suppression
of microglial activity significantly worsens neuronal loss in
several animal models (12, 13), indicating the complexity of
the neuroinflammatory response. We hypothesized that the
actions of estrogen upon microglia are more complex than
simply reducing pro-inflammatory mediator production, and
that it may actively promote pro-resolving/anti-inflammatory
microglial behavior.
Whilst the mechanisms of neuroinflammatory resolution
are relatively underexplored, significant efforts have been
made to understand the drivers of this process in peripheral
inflammation (14). Many mediators have been shown to aid
in inflammatory resolution and repair, but a key driver of
this process is the glucocorticoid-inducible protein annexin A1
(ANXA1), which we and others have shown to exert numerous
pro-resolving/anti-inflammatory effects including promotion of
neutrophil endothelial detachment (15) and apoptosis (16),
monocyte recruitment (17, 18) and macrophage phagocytosis
(19). CNS expression of ANXA1 is primarily localized to
endothelial cells (20) and themicroglia, where we have previously
shown it to be a critical player in microglial efferocytosis (21).
Moreover, several studies have shown that ANXA1 expression in
immune and other cells can be enhanced by estradiol (22–24),
suggesting that the role of this protein in anti-inflammatory/pro-
resolving actions of estradiol merits investigation.
Microglial phagocytosis, the removal of potentially damaging
threats such as invading pathogens or apoptotic cells, is central
to their ability to respond to neuroinflammatory challenge.
We therefore investigated the ability of estrogen to regulate
microglial phagocytic clearance of apoptotic cells in unstimulated
and pro-inflammatory conditions, and the consequences of
estrogen treatment upon microglial phenotype, focussing on the
central pro-resolving actor annexin A1.
MATERIALS AND METHODS
Drugs
Laboratory reagents and culture media were purchased from
Sigma-Aldrich (Poole, UK) unless otherwise stated. The
selective estrogen receptor alpha (ERα) agonist 4,4
′
,4
′′
-(4-
propyl-[1H]-pyrazole-1,3,5–triyl)trisphenol (PPT), the selective
estrogen receptor beta (ERβ) agonist diarylpropionitrile (DPN),
the selective G-protein coupled estrogen receptor (GPER)
agonist (±)-1-[(3aR∗,4S∗,9bS∗)-4-(6-Bromo-1,-3-benzodioxol-
5-yl)-3a,4,5,9b-tetrahydro-3H-cyclop-enta[c]quinolin-8-yl]-
ethanone (G1), the selective ERβ antagonist 4-[2-phenyl-5,7-bis
(trifluoromethyl-)pyrazolo[1,5-a]pyrimidin-3-yl] phenol
(PHTPP) and the selective GPER antagonist (3aS∗,4R∗,9bR∗)-4-
(6-Bromo-1,3-benz-odioxol-5-yl)-3a,4,5,9b-3H-cyclopenta[c]
quinolone (G15) were all purchased from Tocris Bioscience, UK.
Cell Culture
Murine microglial BV2 cells (25) were cultured in RPMI
medium supplemented with 5% fetal calf serum, 100µM non-
essential amino acids, 2mM l-alanyl-glutamine, and 50µg/ml
gentamycin (all ThermoFisher Scientific, Poole, UK) at 37◦C in
5% CO2. PC12 cells (ATCC) were cultured in RPMI medium
supplemented with 10% normal horse serum, 5% fetal calf serum,
100µMnon-essential amino acids, 2mM l-alanyl-glutamine, and
50µg/ml gentamycin (all ThermoFisher Scientific, UK) at 37◦C
in 5% CO2.
Knockdown of AnxA1 Expression
BV2 cells (1 × 105 cells per well) were transfected with
shRNA plasmids targeting murine AnxA1 from the MISSION
TRC shRNA collection (Sigma-Aldrich, St. Louis, MO, USA),
or with an empty plasmid control (termed pKCON). Cells
were transfected for 48 h using FuGENE HD (Promega,
Madison, Wisconsin, USA) according to the manufacturer’s
instructions, followed by selection for stable clones using
puromycin (Promega, Madison, Wisconsin, USA). Transfection
was confirmed by western blot analysis.
Phagocytosis Assay
Phagocytosis was assessed as detailed previously (21).
Briefly, PC12 cells were fluorescently labeled with 5-
chloromethylfluorescein diacetate (CMFDA; Thermofisher
Scientific, UK) according to the manufacturer’s instructions,
and were treated overnight with 80µM 6-hydroxydopamine
hydrobromide or 40µM Na2S2O5 vehicle to induce apoptosis.
Labeled apoptotic/non-apoptotic PC12 cells were then co-
cultured with previously plated BV2 cells at a ratio of 1:3
BV2:PC12 for 2 h at 37◦C under 5% CO2. Co-cultures were
rapidly washed three times with ice-cold PBS to remove non-
phagocytic cells, and cells were either detached by gentle scraping
using a rubber policeman for analysis by imaging cytometer,
or mounted under Mowiol mounting agent for analysis by
immunofluorescence microscopy as described previously (21).
Cells were examined using an ImageStreamx MKII imaging
cytometer and INSPIRE software (Amnis Corporation, Seattle,
WA, USA), collecting a total of 10,000 events per treatment.
Typical examples of phagocytic and non-phagocytic BV2 cells
are presented in Supplementary Figure 1. Imaging cytometer
analysis was confirmed by parallel analysis using microscopy. All
experiments were performed in triplicate.
Primary Microglial Cultures
All animal work was performed under the UKAnimals (Scientific
Procedures) Act, 1986. Primary murine microglial cultures were
prepared from 12-week-old female AnxA1 null (26) and C57BL/6
wild-type mice (n = 6), according to published protocols
(27). Briefly, animals were transcardially perfused with ice-cold
heparinised saline under pentobarbital anesthesia and brains
were removed. Tissue was cut into ∼1 mm3 pieces and digested
by incubation with papain for 30min at 37◦C (1.5 U/ml,
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Sigma, UK). Resulting cell suspensions were purified by filtration
through 0.45µm cell strainers and by density gradient separation
on a 75%:25%:0% Percoll-PBS gradient (GE Johnson, UK).
Following washing in PBS, cells were plated at 1.5× 105 cells/well
in 12-well plates and cultured in DMEM supplemented with
10% FCS, 100mM non-essential amino acids, 2mM L-alanyl-
glutamine, 50 mg/ml gentamycin (all Life Technologies, UK),
and 10 ng/ml M-CSF (ThermoFisher Scientific, UK) at 37◦C
in 5% CO2 for 10 days prior to experimentation. Phagocytosis
assays were performed by microscopy as described above, with
the additional step that cultures were immunostained for Iba1 to
identify microglia as described previously (21).
Flow Cytometry Analysis
BV2 cells were fixed by incubation in 2% formaldehyde for
10min prior to labeling for 45min at 4◦C with anti-AnxA1
50 ng/ml (21), mouse anti-human ERα 4µg/ml (sc-71064,
Santa Cruz Biotechnology Inc., Santa Cruz, USA); mouse
anti-human ERβ 4µg/ml (sc-53494, Santa Cruz Biotechnology
Inc.); goat anti-mouse GPER 5µg/ml (AF5534, R&D Systems
Inc., Minneapolis, USA), APC-conjugated rat anti-mouse CD40
2.5µg/ml, PE-conjugated rat anti-mouse CD206 5µg/ml, or
appropriate isotype controls (Catalog Nos. 17-0401-82 and 12-
2061-82, respectively, both ThermoFisher Scientific, UK). Cells
were then washed in PBS and, where appropriate, incubated at
4◦C for 30min with an AF488-conjugated secondary antibody
(AnxA1, ERα, ERβ: goat anti-mouse IgG, GPER chicken anti-
goat IgG, both diluted 1:300). Inclusion of 0.025% saponin at all
stages of the immunostaining process was used to define total
vs. surface AnxA1 expression. In all cases, 20,000 events were
acquired using a FACSCalibur flow cytometer (BD Biosciences,
Cowley, UK) equipped with a 488 nm argon laser; data was
analyzed using FlowJo 8.8.2 software (Treestar Inc., Stanford,
CA, USA) with positive events being compared to appropriate
secondary antibody or isotype controls.
Quantitative RT-PCR
Total RNA was extracted using the RNeasy mini kit and
genomic DNA was removed by on-column digestion using the
RNase-Free DNase set, following the manufacturer’s instructions
(Qiagen, Crawley, UK). cDNA was synthesized using 1 µg of
pooled RNA from at least three replicates using SuperScript
III Reverse Transcriptase (ThermoFisher Scientific, UK). Real-
time PCR was performed in triplicate, with 200 ng of cDNA
per well, 1 µl of primers, and Power SYBR Green PCR
master mix (Applied Biosystems, Warrington, UK), using
the ABI Prism 7900HT sequence detection system (Applied
Biosystems, UK). The following QuantiTect primers (Qiagen,
UK) were used: ribosomal protein L32 (Rpl32; QT00131992),
AnxA1 (QT00145915). A dissociation step was always included
to confirm the absence of unspecific products. Relative
expression was calculated as 2−11CT using Rpl32 as an
endogenous control.
ELISA
TNFα, was assayed by murine-specific sandwich ELISA using
commercially available kits, according to the manufacturer’s
protocols (ThermoFisher Scientific, UK). AnxA1 was assayed
using an in-house ELISA. Briefly, a 96-well plate coated
with 10 µg/well of a murine monoclonal anti-ANXA1 Ab
was blocked with 1% FCS in 50mM Na2CO3 and 50mM
NaHCO3 (pH 9.6) for 1 h at 37◦C, washed, and samples
and a standard series of hrANXA1 were then added to the
plate in triplicate and incubated for 1 h at 37◦C. Wells were
washed, and incubated with a rabbit anti-ANXA1 polyclonal Ab,
diluted 1:1,000 (Thermofisher Scientific, UK) for 1 h at 37◦C.
Wells were washed and incubated with HRP-conjugated sheep
anti-rabbit polyclonal antiserum (1:500, Bio-Rad Antibodies,
UK) for 1 h at 37◦C. Plates were washed and incubated
with 3,3
′
,5,5
′
-tetramethylbenzidine (Sigma-Aldrich, UK) for
10min at room temperature; reactions were stopped by
addition of 0.5M H2SO4. A CLARIOstar spectrophotometer
(BMG Labtech, Germany) was used to measure absorbance
at 450 nm; minimum sensitivity was 1.4 ng/ml. Nitric oxide
production was assessed using the Griess reaction for its
stable proxy nitrite (28). Briefly, 100 µl/well culture medium
was incubated with an equal volume of Griess reagent (1%
sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride,
5% phosphoric acid) for 15min, prior to measurement of
absorbance at 540 nm using a CLARIOstar spectrophotometer
(BMG Labtech, Germany). Nitrite production was determined by
comparison with a NaNO2 standard curve; minimum sensitivity
was 3 µM.
Western Blot Analysis
Samples boiled in 6× Laemmli buffer were subjected to
standard SDS-PAGE (10%) and electrophoretically blotted
onto Immobilon-P polyvinylidene difluoride membranes
(Merck, UK). Total protein was quantified using Ponceau
S staining (Merck, UK) and membranes were blotted for
AnxA1 using an antibody raised against murine AnxA1
(1:1,000; ThermoFisher Scientific, UK) in Tris-buffer saline
solution containing 0.1% Tween-20 and 5% (w/v) non-
fat dry milk overnight at 4◦C. Membranes were washed
with Tris-buffer saline solution containing 0.1% Tween-
20, and incubated with secondary antibody (horseradish
peroxidase–conjugated goat anti-rabbit 1:5,000; ThermoFisher
Scientific, UK), for 2 h at room temperature. Proteins were
then detected using the enhanced chemiluminescence
detection kit and visualized on Hyperfilm (Amersham
Biosciences, Amersham, UK). Films were digitized and
analyzed using ImageJ 1.51w software (National Institutes
of Health).
Statistical Analysis
All quantified data are derived from at least three
independent experiments, performed in triplicate, and
are expressed as the mean ± standard error of the
mean. Data were analyzed by one- or two-way ANOVA
as appropriate, with post hoc comparison using Tukey’s
HSD t-test. In all cases, p ≤ 0.05 was taken as indicating
statistical significance.
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RESULTS
Estradiol Modulates Microglial
Phagocytosis in a Receptor-Specific
Manner
Initial analysis by flow cytometry confirmed the expression of
all three principal estrogen receptors (ERα, ERβ, and GPER) are
expressed by BV2 microglia (Figure 1A). We then investigated
the ability of estrogen to modulate the phagocytosis of apoptotic
PC12 cells by BV2 cells. Exposure of BV2 microglia to 17β-
estradiol dose- and time-dependently enhanced the phagocytic
uptake of apoptotic cells, with greatest impact after 16 h
treatment and at 100 nM (Figures 1B,C).
To determine which of the three estrogen receptors were
responsible for the pro-phagocytic effects of estradiol, we
examined the effect of treatment with specific pharmacological
agonists. Treatment of BV2 cells for 16 h with the ERα selective
agonist PPT was without effect (Figure 2A) but treatment
with the ERβ agonist DPN significantly and dose-dependently
enhanced phagocytosis (Figure 2B). In contrast, 16 h exposure to
the GPER agonist G1 dose-dependently attenuated the ability of
microglia to phagocytose apoptotic cells (Figure 2C). Furthering
this analysis, we studied the effects of the ERβ antagonist
PHTPP or the GPER antagonist G15 (each administered at
their respective IC50 values) upon the response of BV2 cells
to estradiol. Pre-treatment with either antagonist alone had no
effect on phagocytosis of apoptotic cells, but administration of
PHTPP almost completely inhibited the pro-phagocytic effect
of estradiol (Figure 2D). In contrast, pre-treatment with G15
significantly potentiated apoptotic cell clearance by BV2 cells
treated with estradiol (Figure 2E).
To validate the pro-phagocytic effects of estrogen, we
examined whether primary microglia derived from adult mouse
brain would respond similarly to estradiol or its receptor-
specific mimetics. Initial studies confirmed that expression of
all three principal estrogen receptor subtypes could be detected
in primary murine microglia. (Figure 2F). Primary microglia
were significantly more efficient than BV2 cells at phagocytosing
apoptotic PC12 cells, but they nonetheless responded in a similar
way to estrogen receptor ligand treatment, with estradiol or
DPN treatment both potentiating phagocytosis and G1 treatment
impairing it (Figure 2G). Together, these data strongly indicate
that estradiol exerts dual, and opposing, effects upon microglial
phagocytosis acting via both ERβ and GPER.
Estradiol Promotes Microglial
Phagocytosis Through the Mobilization of
the Pro-Phagocytic Factor, Annexin A1
We have previously shown the microglia-secreted protein
annexin A1 (AnxA1) to serve as an important “eat me” signal for
phagocytosis following its release frommicroglia and subsequent
binding to exposed phosphatidylserine on the apoptotic cell
surface (21). As we and others have shown this protein tomediate
some of the actions of estradiol in other contexts (22, 29),
we hypothesized that mobilization of AnxA1 may underlie the
ERβ-dependent pro-phagocytic effects of estradiol. We therefore
compared the effects of the hormone upon phagocytic behavior of
primary microglia derived from adult wild-type and AnxA1 null
mice. Pre-treatment of primarymicroglia fromwild-type animals
with estradiol significantly increased apoptotic cell phagocytosis
as expected, but this was not the case in microglia from AnxA1
null mice, where estradiol not only failed to augment microglial
phagocytosis, but actually inhibited it (Figure 3A).
Given the importance of AnxA1 secretion from microglia
for efficient phagocytosis, we investigated how treatment with
estrogen or its receptor-specificmimetics would affect the cellular
localization of the protein. Exposure of BV2 cells to either
estradiol or the ERβ agonist DPN increased AnxA1 mRNA
and total protein content (Figures 3B,C), and in the case of
DPN also increased cell surface AnxA1 expression (Figure 3D).
Moreover, both ligands significantly induced protein release into
the culture medium (Figure 3E). In contrast, treatment with the
GPER agonist G1 had no significant effect upon AnxA1 mRNA
(Figure 3B) or secreted protein (Figure 3E), but significantly
enhanced total AnxA1 content (Figure 3C) whilst decreasing
cell surface protein (Figure 3D), strongly suggesting increased
intracellular accumulation of the protein.
Estradiol Regulates Inflammatory
Microglial Activation, Promoting
Resolution
Outside of development and certain defined areas of the brain,
non-phlogistic neuronal apoptosis is rare, with cell death being
more commonly associated with neuroinflammation and disease
(30). We therefore investigated the effects of estradiol upon
microglia under inflammatory conditions, modeled by exposure
to bacterial endotoxin (21, 31). As previously described (21),
pre-exposure of BV2 cells to 50 ng/ml LPS for 18 h significantly
increased the inappropriate phagocytosis of non-apoptotic cells,
but this was markedly attenuated by subsequent (2 h after LPS
stimulation) addition of estradiol or DPN, but not G1, indicative
of an ERβ-mediated action (Figure 4A). Similarly, LPS-induced
production of intracellular reactive oxygen species was reduced
by treatment with estradiol and DPN, but not G1 (Figure 4B). In
contrast, estradiol, DPN and G1 were all able to attenuate LPS-
induced production of the inflammatory mediators TNFα and
nitric oxide (Figures 4C,D). Characterization of BV2 cell surface
markers of inflammatory phenotype revealed that treatment with
estradiol, DPN or G1 could attenuate LPS-induced expression
of the pro-inflammatory marker CD40 (Figure 4E, typical
profiles Supplementary Figure 2A) and prevent LPS-induced
suppression of the anti-inflammatory marker CD206 (Figure 4F,
typical profiles Supplementary Figure 2B). Together these data
suggest that estrogen receptor activation could limit the pro-
inflammatory stimulation of microglia, with significant roles for
both ERβ and G1.
Given the major pro-resolving and anti-inflammatory
functions of AnxA1 identified from studies of other immune
cells (32), and our previous detection of a key mediating role for
this protein in estrogen-induced phagocytosis, we hypothesized
that it may similarly mediate the anti-inflammatory actions
of estrogen and its receptor mimetics. We therefore stably
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FIGURE 1 | Estrogen promotes microglial phagocytosis of apoptotic cells. (A) BV2 cells express all three principal estrogen receptors, ERα, ERβ, and GPER, as
determined by flow cytometry. Data are representative histograms of n = 3 independent experiments. Exposure of BV2 cells to 17β-estradiol enhances their ability to
phagocytose apoptotic (gray) but not non-apoptotic (white) PC12 cells in a (B) dose and (C) time-dependent manner; data are mean ± sem, n = 3, *p < 0.05 vs.
untreated controls.
transfected BV2 cells with a lentiviral vector bearing an shRNA
sequence targeting AnxA1 to reduce expression of the protein
(Supplementary Figure 3) and investigated whether the anti-
inflammatory effects of estrogen or its mimetics weremaintained.
Knock-down of AnxA1 in this way significantly impaired the
ability of estradiol, DPN, or G1 to reverse LPS-induced TNFα
release (Figure 5A), but did not affect the inhibitory effects
of estradiol, DPN, or G1 on LPS-induced nitric oxide release
(Figure 5B). Suppression of AnxA1 expression did however,
reverse the effects of estradiol, DPN, or G1 on both CD40
(Figure 5C) and CD206 (Figure 5D) expression, confirming an
important role for AnxA1 in mediating many, although not all,
of the anti-inflammatory actions of estrogen.
DISCUSSION
Estrogen is increasingly recognized as a powerful modulator of
immune cell activity, able to regulate cells of both the innate
(33) and adaptive (2) arms of the immune system, actions which
contribute to the sex differences commonly seen in inflammatory
disorders. Inflammatory diseases of the CNS, including such
major conditions as Alzheimer’s disease, Parkinson’s disease,
and multiple sclerosis, have similarly been shown to be sexually
dimorphic in incidence and/or symptom severity (34, 35). Whilst
multiple factors undoubtedly contribute to these sex differences,
direct neuroprotective effects of estrogen are strongly supported
(36, 37). For many years, studies have focussed on the directly
neuroprotective actions of estrogen upon neurones (38), but
more recent attention has been given to the modulatory effects
of the hormone upon microglial behavior, given the importance
of these cells in many neurological disorders (31, 39–41). In this
study, we have identified the ability of estrogen to modulate a key
aspect of microglial function in disease, the removal of apoptotic
cells. We describe a clear, receptor-specific, modulatory action
of the principal estrogen 17β-estradiol upon microglial clearance
of apoptotic cells, and highlight the ability of the steroid to
suppress inflammatorymicroglial activation.Moreover, we reveal
a central role for the powerful pro-resolving protein AnxA1
in mediating both the pro-efferocytosis and anti-inflammatory
effects of estrogen upon microglia.
Clearance of apoptotic cells by phagocytosis is critical for
the maintenance of healthy tissue, as apoptotic cells that are
not removed will progress to secondary necrosis and become
significant inflammatory foci themselves (42). Microglia are
the principal phagocytes of the CNS and play a central role
in this process, a particularly important action given the
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FIGURE 2 | Estrogen has receptor specific effects upon microglial phagocytosis. (A–C) Treatment of BV2 cells for 16 h with estradiol (E2) or selective agonists for (A)
ERα (PPT), (B) ERβ (DPN) or (C) GPER (G1) revealed receptor dependent effects upon microglial phagocytosis, with activation of ERβ promoting and GPER inhibiting
phagocytic activity; ERα activation had no effect on phagocytosis; data are means ± sem, n = 3, *p < 0.05 vs. untreated controls. (D) Pre-treatment of microglia with
the selective ERβ antagonist PHTPP (200 nM, 15min pre-treatment) prevented the stimulatory effect of estradiol (100 nM, 16 h) upon microglial phagocytosis of
(Continued)
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FIGURE 2 | apoptotic cells; data are means ± sem, n = 3, *p < 0.05 vs. untreated controls, +p < 0.05 vs. 17β-estradiol treatment. (E) Pre-treatment of microglia
with the selective GPER antagonist G1 (200 nM, 15 minute pre-treatment) enhanced the stimulatory effect of estradiol (100 nM, 16 h) upon microglial phagocytosis of
apoptotic cells; data are means ± sem, n = 3, *p < 0.05 vs. untreated controls, +p < 0.05 vs. 17β-estradiol treatment. (F) Expression of all three estrogen receptors
ERα, ERβ and GPER is detectable in primary murine microglia. (G) Treatment of primary murine microglia for 16 h with 17β-estradiol or DPN enhanced phagocytosis
of apoptotic cells, whilst treatment with G1 inhibited phagocytosis; data are means ± sem, n = 3, *p < 0.05 vs. untreated controls, +p < 0.05 vs.
17β-estradiol treatment.
FIGURE 3 | The pro-phagocytic effects of estrogen via ERβ require mobilization of annexin A1. (A) Treatment of primary microglia from wild-type mice with
17β-estradiol (100 nM, 16 h) promotes phagocytosis of apoptotic PC12 cells, whereas similar treatment of AnxA1−/− primary microglia causes a significant further
inhibition in their phagocytic ability; data are means ± sem, n = 3, *p < 0.05 vs. untreated controls, +p < 0.05 vs. similarly treated wild-type group. (B) Treatment of
BV2 cells for 16 h with 17β-estradiol or the ERβ agonist DPN, but not the GPER agonist G1, enhances production of AnxA1 mRNA; data are means ± sem, n = 3, *p
< 0.05 vs. untreated controls. (C) Treatment of BV2 cells for 16 h with 17β-estradiol, DPN or G1 enhances total cellular AnxA1 content; data are means ± sem, n = 3,
*p < 0.05 vs. untreated controls. (D) Treatment of BV2 cells for 16 h with DPN enhances, whilst similar treatment with G1 reduces, surface expression of AnxA1; data
are means ± sem, n = 3, *p < 0.05 vs. untreated controls. (E) Treatment of BV2 cells for 16 h with 17β-estradiol or DPN but not G1 enhances release of AnxA1 into
the culture medium; data are means ± sem, n = 3, *p < 0.05 vs. untreated controls.
susceptibility of neurones to inflammatory damage (43). Our data
reveal estrogen to strongly potentiate microglial phagocytosis of
apoptotic cells, acting through induction of AnxA1 expression
and secretion. We have previously shown AnxA1 to induce a
non-phlogistic phenotype in microglia post-phagocytosis (21),
strongly suggesting that itsmodulation by estrogen is a significant
component of the hormone’s neuroprotective effects. Previous
work has suggested that estrogen can promote phagocytosis by
peripheral macrophages (44, 45), acting primarily through ERα.
In contrast, whilst we identified ERα expression in microglia,
activation of this receptor with the specific ERα agonist PPT had
little impact on phagocytosis, with much clearer roles for the
alternative estrogen receptors ERβ and GPER.
Whilst the overall effect of 17β-estradiol was to stimulate
microglial phagocytosis, pharmacological analysis of the specific
receptors involved in this process revealed an intriguing
distinction between ERβ and GPER, with ERβ acting to promote
phagocytosis and GPER inhibiting it. The mechanism underlying
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FIGURE 4 | Estrogen promotes an anti-inflammatory microglial phenotype. (A) Pre-treatment of BV2 cells for 2 h with 50 ng/ml bacterial lipopolysaccharide (LPS)
induces the phagocytosis of non-apoptotic PC12 cells, an effect reversed by subsequent treatment (16 h) with either 17β-estradiol or DPN, but not G1; data are
means ± sem, n = 3, *p < 0.05 vs. respective control cells, +p < 0.05 vs. LPS treatment alone. (B) Treatment of BV2 cells with 17β-estradiol or DPN but not G1
(16 h) suppresses LPS-induced reactive oxygen species production (2 h pre-treatment); data are means ± sem, n = 3, *p < 0.05 vs. LPS-treated controls. (C)
Treatment of BV2 cells (16 h) with 17β-estradiol or DPN but not G1 (16 h) limits LPS-induced production of the pro-inflammatory cytokine TNFα (2 h pre-treatment);
data are means ± sem, n = 3, *p < 0.05 vs. respective control cells, +p < 0.05 vs. LPS treatment alone. (D) Treatment of BV2 cells with 17β-estradiol, DPN or G1
(16 h) suppresses LPS-induced production of nitrite (2 h pre-treatment; baseline nitrite production was below detection limits); data are means ± sem, n = 3, *p <
0.05 vs. LPS-treated control cells. (E) Treatment of BV2 cells with 17β-estradiol, DPN or G1 (16 h) suppresses LPS-induced surface expression of the
pro-inflammatory marker CD40 (2 h pre-treatment); data are means ± sem, n = 3, *p < 0.05 vs. untreated control cells, +p < 0.05 vs. LPS-treated control cells. (F)
Treatment of BV2 cells with 17β-estradiol, DPN or G1 (16 h) reverses the LPS-induced loss of surface expression of the anti-inflammatory marker CD206 (2 h
pre-treatment); data are means ± sem, n = 3, *p < 0.05 vs. respective control cells, +p < 0.05 vs. LPS treatment alone.
this effect appears to revolve around differential effects upon
AnxA1 localization; ERβ activation increased AnxA1 synthesis
and release, whilst GPER stimulation led to intracellular AnxA1
accumulation and a reduction in secreted protein. The pro-
phagocytic actions of AnxA1 are dependent upon its secretion
from microglia and consequent binding to phosphatidylserine
on apoptotic target cells (21), hence the negative effects of
GPER stimulation upon AnxA1 release presumably underlies
the effects of this receptor upon phagocytosis. Interestingly, this
dichotomy of effect was not replicated in the effects of estrogen
receptor activation upon microglial phenotype, with both ERβ
and GPER selective ligands being equipotent in ameliorating
LPS-induced pro-inflammatory signs. This finding accords well
with published studies that show exogenous administration
of the GPER agonist G1 to prevent inflammatory microglial
activation in vivo (46–48), and that identify a mediatory role for
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FIGURE 5 | The anti-inflammatory effects of estrogen are largely dependent upon AnxA1 expression. (A) Stable transfection of BV2 cells with an shRNA sequence
targeting AnxA1, but not with an empty plasmid control (pKCON), inhibits the ability of estradiol, DPN or G1 (16 h) to suppress LPS-induced TNFα production (2 h
pre-treatment); data are means ± sem, n = 3, *p < 0.05 vs. LPS-treated control cells. (B) Neither stable transfection of BV2 cells with an empty plasmid control
(pKCON) nor with an shRNA sequence targeting AnxA1 affects the ability of estradiol, DPN or G1 (16 h) to suppress LPS-induced nitrite production (2 h
pre-treatment); data are means ± sem, n = 3, *p < 0.05 vs. LPS-treated control cells. (C) Stable transfection of BV2 cells with an shRNA sequence targeting AnxA1,
but not with an empty plasmid control (pKCON), inhibits the ability of estradiol, DPN or G1 (16 h) to suppress LPS-induced surface expression of the pro-inflammatory
marker CD40 (2 h pre-treatment); data are means ± sem, n = 3, *p < 0.05 vs. LPS-treated control cells. (D) Stable transfection of BV2 cells with an shRNA sequence
targeting AnxA1, but not with an empty plasmid control (pKCON), inhibits the ability of estradiol, DPN or G1 (16 h) to reverse LPS-suppressed expression of the
anti-inflammatory marker CD206 (2 h pre-treatment); data are means ± sem, n = 3, *p < 0.05 vs. LPS-treated control cells.
GPER in the anti-inflammatory effects of estrogen in cerebral
ischaemia (49). These anti-inflammatory effects of estrogen or
its receptor-specific mimetics again appeared to be mediated
in large part through AnxA1, with microglia stably bearing
AnxA1-targeting shRNA sequences showing a clear impairment
in many of the anti-inflammatory actions of estrogen and
its mimetics.
Our findings reinforce the importance of AnxA1 in the
nervous system response to injury (50), with microglia
lacking AnxA1 being severely impaired in their phagocytic
ability. Moreover, such microglia show a markedly altered
response to estradiol with exposure to the hormone actually
inhibiting phagocytosis, and inducing only limited anti-
inflammatory actions. These data thus reinforce the complexity
of the systems that have evolved to regulate microglial
function. Moreover, this work highlights the potent regulatory
action of estrogen upon AnxA1 expression and activity
(22, 23), and extends this role to the cells of the CNS.
Thus, complementing its long-studied role as a mediator
of glucocorticoid immunomodulatory action (32), our results
further emphasize the importance of AnxA1 in the anti-
inflammatory effects of femalere sex hormones.
Local up-regulation of aromatase expression and consequent
estrogen production is a key part of the response to CNS
injury (4, 5, 51), acting to limit damage and preserve tissue
integrity. Where and how estrogen exerts its protective effects
is less clear however, but blockade of estrogen production by
genetic deletion of aromatase leads to significantly enhanced
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post-injury gliosis (52). The role of microglia in such injury-
induced gliosis is complex, as these cells show dramatic and
dynamic changes in phenotype (53), and have the potential to be
both harmful and protective to surrounding neurones (54). Our
findings suggest that a major action of estrogen upon microglia
is to promote their more protective functions, enhancing the
efferocytosis of damaged/dying cells and limiting expression
of pro-inflammatory features. These actions are supported by
numerous studies showing exogenous estrogen to be protective
in models of neuroinflammatory/neurotoxic damage (37, 55),
and particularly by previous work identifying estrogen as
an anti-inflammatory modifier of microglial phenotype (56–
62). Together with these reports, our study places estrogen
as a significant pro-resolving mediator within the brain,
acting to stimulate the removal of cellular debris post-
injury and to promote an anti-inflammatory environment,
highlighting its role as a major part of the brain’s endogenous
defense mechanisms.
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